neoplasm
• fewer transgenic mice develop skin tumors after topical application of DMBA and PMA than Trp53 heterozygote controls
• median time to tumor formation is 25 weeks versus 16 weeks for the Trp53 heterozygote controls
• a lower percentage of mice (71% versus 89%) have tumors 32-weeks after DMBA application compared with controls
• mean tumor burden is 2.29 tumors per mouse compared to 3.0 tumors in controls
• tumor regression is not observed in transgenic mice whereas 10% of tumors in non-transgenic mice regress
• transgenic mice have an increased incidence of atypical papillomas that progress to squamous cell carcinoma
|
homeostasis/metabolism
• fewer transgenic mice develop skin tumors after topical application of DMBA and PMA than Trp53 heterozygote controls
• median time to tumor formation is 25 weeks versus 16 weeks for the Trp53 heterozygote controls
• a lower percentage of mice (71% versus 89%) have tumors 32-weeks after DMBA application compared with controls
• mean tumor burden is 2.29 tumors per mouse compared to 3.0 tumors in controls
• tumor regression is not observed in transgenic mice whereas 10% of tumors in non-transgenic mice regress
• transgenic mice have an increased incidence of atypical papillomas that progress to squamous cell carcinoma
|